A study in the Journal of Nuclear Medicine reported that repeating PSMA PET imaging after an initial negative scan changed treatment decisions for nearly half of patients with prostate cancer recurrence. The work evaluated how a second PSMA PET could identify clinically actionable findings that were missed on the first imaging round. The findings support an emerging workflow where repeat imaging is used to refine management rather than defaulting to a single negative assessment, potentially altering downstream treatments and selection.